For the Inventor, By the Inventor

Enter assignee name

Farmingdale, NY, United States of America

Enzo Therapeutics, Inc.

USPTO Granted Patents = 31

CIPO Patents = 7

EPO Patents = 12

Forward Citations = 157

Loading Chart...

Loading Chart...

25 inventors (with patents filed for the assignee):

Robert Elliot Zipkin (9 out of 13 patents)

Sarah Spiegel (9 out of 10 patents)

Jeffrey Kroll Adams (9 out of 15 patents)

4. Yaron Ilan (9 out of 47 patents)

5. Elazar S Rabbani (6 out of 122 patents)

6. James J Donegan (5 out of 84 patents)

7. Dakai Liu (5 out of 28 patents)

8. Maya Margalit (4 out of 4 patents)

9. Joshua Rabbani (3 out of 14 patents)

10. Xiaofeng Li (3 out of 17 patents)

11. Eran Elinav (3 out of 5 patents)

12. Ari Zimran (2 out of 3 patents)

13. Dean L Engelhardt (2 out of 18 patents)

14. James G Wetmur (2 out of 7 patents)

15. Robin S Quartin (2 out of 3 patents)

31 patents: Sort by Forward Citations

1. 11938167 - Pharmaceutical compositions and methods targeting Wnt pathway proteins (2024-03-26),

2. 11737992 - Sphingosine kinase Type 1 inhibitors and uses thereof (2023-08-29),

3. 11167011 - Methods for treating bone loss using sclerostin peptides (2021-11-09),

4. 10945971 - Sphingosine kinase type 1 inhibitors and uses thereof (2021-03-16),

5. 10723797 - Methods for treating psoriasis (2020-07-28),

6. 10639324 - Glucocerebroside treatment of disease (2020-05-05),

7. 10624863 - Sphingosine kinase type 1 inhibitors and uses thereof (2020-04-21),

8. 10456370 - Sphingosine kinase type 1 inhibitors and uses thereof (2019-10-29),

9. 10328120 - Pharmaceutical compositions targeting WNT pathway proteins (2019-06-25),

10. 10166204 - Sphingosine kinase type 1 inhibitors and uses thereof (2019-01-01),

11. 9974758 - Sphingosine kinase type 1 inhibitors and uses thereof (2018-05-22),

12. 9907810 - Glucocerebroside treatment of liver disorders (2018-03-06),

13. 9744185 - Glucocerebroside treatment of liver disorders (2017-08-29),

14. 9717754 - Glucocerebroside treatment of disease (2017-08-01),

15. 9388121 - Sphingosine kinase type 1 inhibitors (2016-07-12),

Enzo Therapeutics, Inc. is a leading biotechnology company specializing in the development of innovative therapeutics for various diseases. With a focus on precision medicine, Enzo Therapeutics aims to transform patient care through cutting-edge research and clinical advancements. Their team of dedicated scientists and healthcare professionals work diligently to create novel treatments that address unmet medical needs. Visit their website to learn more about Enzo Therapeutics and their groundbreaking work.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

31 Patents

#6 in Farmingdale, NY

#591 in New York

#10,560 in US

#20,639 in the World

Farmingdale, NY, United States of America

Enzo Therapeutics, Inc.

Forward Citations = 157

25 inventors:

Robert Elliot Zipkin (9 out of 13 patents)

Sarah Spiegel (9 out of 10 patents)

Jeffrey Kroll Adams (9 out of 15 patents)

4. Yaron Ilan (9 out of 47 patents)

5. Elazar S Rabbani (6 out of 122 patents)

Please report any incorrect information to support@idiyas.com

Loading…